Top

International Journal of Clinical Oncology

Published in:

01-10-2016 | Original Article

Prognostic value of glucosylceramide synthase and P-glycoprotein expression in oral cavity cancer

Authors: Ji Won Kim, Yangsoon Park, Jong-Lyel Roh, Kyung-Ja Cho, Seung-Ho Choi, Soon Yuhl Nam, Sang Yoon Kim

Published in: International Journal of Clinical Oncology | Issue 5/2016

Abstract

Background

Glucosylceramide synthase (GCS) and P-glycoprotein (P-gp) overexpression are associated with multidrug resistance in several human cancers. This study investigated the prognostic value of GCS and P-gp in oral cavity squamous cell carcinoma (OSCC).

Methods

The association between GCS and P-gp overexpression and clinical outcomes was assessed in 186 human clinical specimens of primary tumors obtained from curative surgery. Immunohistochemistry staining results were scored as high or low for GCS, and positive or negative for P-gp. Univariate and multivariate analyses using the Cox proportional hazards model were conducted to assess the significance of differences in recurrence or survival outcomes between variables.

Results

GCS overexpression was observed in 128 (68.8 %) patients and P-gp overexpression in 43 (23.1 %) patients. High GCS expression was significantly correlated with P-gp immunopositivity (P = 0.005). GCS and P-gp overexpression was significantly correlated with cervical nodal metastasis (P < 0.05). Univariate analyses showed that tumor lymphovascular invasion, positive neck lymph nodes, advanced overall TNM stage, high GCS expression, and P-gp immunopositivity were associated with poor locoregional control (LRC), disease-free survival (DFS), and overall survival (OS) (P < 0.05). Multivariate analyses showed that lymphovascular invasion, nodal positivity, and P-gp overexpression remained independent prognostic variables for LRC, DFS, and OS, and that GCS expression was an independent predictor of LRC and DFS (P < 0.05).

Conclusion

GCS and P-gp expression is associated with poor prognosis, suggesting suitability as novel biomarkers in OSCC.

Available only for authorised users

Sigel RL, Miller KD, Jemal A (2015) Cancer statistics, 2015. CA Cancer J Clin 65:5–29CrossRef

Sano D, Myers JN (2007) Metastasis of squamous cell carcinoma of the oral tongue. Cancer Metastasis Rev 26:645–662CrossRefPubMed

Murthy V, Agarwal JP, Laskar SG et al (2010) Analysis of prognostic factors in 1180 patients with oral cavity primary cancer treated with definitive or adjuvant radiotherapy. J Cancer Res Ther 6:282–289CrossRefPubMed

Kang H, Kiess A, Chung CH (2015) Emerging biomarkers in head and neck cancer in the era of genomics. Nat Rev Clin Oncol 12:11–26CrossRefPubMed

da Silva SD, Ferlito A, Takes RP et al (2011) Advances and applications of oral cancer basic research. Oral Oncol 47:783–791CrossRefPubMed

Oliveira LR, Ribeiro-Silva A (2011) Prognostic significance of immunohistochemical biomarkers in oral squamous cell carcinoma. Int J Oral Maxillofac Surg 40:298–307CrossRefPubMed

Mizutani T, Masuda M, Nakai E et al (2008) Genuine functions of P-glycoprotein (ABCB1). Curr Drug Metab 9:167–174CrossRefPubMed

Sikic BI, Fisher GA, Lum BL et al (1997) Modulation and prevention of multidrug resistance by inhibitors of P-glycoprotein. Cancer Chemother Pharmacol 40(Suppl):S13–S19CrossRefPubMed

Sagol O, Yavuzsen T, Oztop I et al (2005) The effect of apoptotic activity, survivin, Ki-67, and P-glycoprotein expression on prognosis in pancreatic carcinoma. Pancreas 30:343–348CrossRefPubMed

10.

Wang B, Li XQ, Ma X et al (2008) Immunohistochemical expression and clinical significance of P-glycoprotein in previously untreated extranodal NK/T-cell lymphoma, nasal type. Am J Hematol 83:795–799CrossRefPubMed

11.

Rocco A, Compare D, Liguori E et al (2012) MDR1-P-glycoprotein behaves as an oncofetal protein that promotes cell survival in gastric cancer cells. Lab Invest 92:1407–1418CrossRefPubMed

12.

Ralhan R, Swain RK, Agarwal S et al (1999) P-glycoprotein is positively correlated with p53 in human oral pre-malignant and malignant lesions and is associated with poor prognosis. Int J Cancer 84:80–85CrossRefPubMed

13.

Li DW, Gao S, Shen B et al (2011) Effect of apoptotic and proliferative indices, P-glycoprotein and survivin expression on prognosis in laryngeal squamous cell carcinoma. Med Oncol 28(Suppl 1):S333–S340CrossRefPubMed

14.

Shabbits JA, Mayer LD (2002) P-glycoprotein modulates ceramide-mediated sensitivity of human breast cancer cells to tubulin-binding anticancer drugs. Mol Cancer Ther 1:205–213PubMed

15.

Ichikawa S, Sakiyama H, Suzuki G et al (1996) Expression cloning of a cDNA for human ceramide glucosyltransferase that catalyzes the first glycosylation step of glycosphingolipid synthesis. Proc Natl Acad Sci USA 93:4638–4643CrossRefPubMedPubMedCentral

16.

Morad SA, Cabot MC (2013) Ceramide-orchestrated signalling in cancer cells. Nat Rev Cancer 13:51–65CrossRefPubMed

17.

Liu YY, Han TY, Giuliano AE et al (2001) Ceramide glycosylation potentiates cellular multidrug resistance. FASEB J 15:719–730CrossRefPubMed

18.

Juul N, Szallasi Z, Eklund AC et al (2010) Assessment of an RNA interference screen-derived mitotic and ceramide pathway metagene as a predictor of response to neoadjuvant paclitaxel for primary triple-negative breast cancer: a retrospective analysis of five clinical trials. Lancet Oncol 11:358–365CrossRefPubMed

19.

Zhang X, Wu X, Su P et al (2012) Doxorubicin influences the expression of glucosylceramide synthase in invasive ductal breast cancer. PLoS One 7:e48492CrossRefPubMedPubMedCentral

20.

Sun CC, Zhang Z, Zhang SY et al (2012) Up-regulation of glucosylceramide synthase in urinary bladder neoplasms. Urol Oncol 30:444–449CrossRefPubMed

21.

Liu YY, Patwardhan GA, Xie P et al (2011) Glucosylceramide synthase, a factor in modulating drug resistance, is overexpressed in metastatic breast carcinoma. Int J Oncol 39:425–431PubMedPubMedCentral

22.

Gouazé V, Liu YY, Prickett CS et al (2005) Glucosylceramide synthase blockade down-regulates P-glycoprotein and resensitizes multidrug-resistant breast cancer cells to anticancer drugs. Cancer Res 65(9):3861–3867CrossRefPubMed

23.

Edge SB, Byrd DR, Compton CC et al (2010) AJCC Cancer Staging Manual, 7th edn. Springer-Verlag, New York, pp 29–40

24.

Rabkin D, Chhieng DC, Miller MB et al (1995) P-glycoprotein expression in the squamous cell carcinoma of the tongue base. Laryngoscope 105:1294–1299CrossRefPubMed

25.

Warnakulasuriya S, Jia C, Johnson N et al (2000) p53 and P-glycoprotein expression are significant prognostic markers in advanced head and neck cancer treated with chemo/radiotherapy. J Pathol 191:33–38CrossRefPubMed

26.

Uematsu T, Hasegawa T, Hiraoka BY et al (2001) Multidrug resistance gene 1 expression in salivary gland adenocarcinomas and oral squamous-cell carcinomas. Int J Cancer 92:187–194CrossRefPubMed

27.

Soni S, Pande P, Shukla NK et al (2002) Coexpression of Ets-1 and p53 in oral carcinomas is associated with P-glycoprotein expression and poor prognosis. J Cancer Res Clin Oncol 128:336–342CrossRefPubMed

28.

Friedrich RE, Punke C, Reymann A (2004) Expression of multi-drug resistance genes (mdr1, mrp1, bcrp) in primary oral squamous cell carcinoma. In Vivo 18:133–147PubMed

29.

Larbcharoensub N, Leopairat J, Sirachainan E et al (2008) Association between multidrug resistance-associated protein 1 and poor prognosis in patients with nasopharyngeal carcinoma treated with radiotherapy and concurrent chemotherapy. Hum Pathol 39:837–845CrossRefPubMed

30.

Furusaka T, Sasaki CT, Matsuda A et al (2013) Multidrug resistance in mucoepidermoid carcinoma of the parotid gland–immunohistochemical investigations of P-glycoprotein expression. Acta Otolaryngol 133:552–557CrossRefPubMed

31.

Warta R, Theile D, Mogler C et al (2014) Association of drug transporter expression with mortality and progression-free survival in stage IV head and neck squamous cell carcinoma. PLoS One 9:e108908CrossRefPubMedPubMedCentral

32.

Liu YY, Gupta V, Patwardhan GA et al (2010) Glucosylceramide synthase upregulates MDR1 expression in the regulation of cancer drug resistance through cSrc and beta-catenin signaling. Mol Cancer 9:145CrossRefPubMedPubMedCentral

33.

Fasanaro E, Staffieri C, Cappellesso R et al (2015) Prognostic significance of serine-phosphorylated STAT3 expression in pT1-T2 oral tongue carcinoma. Clin Exp Otorhinolaryngol 8:275–280CrossRefPubMedPubMedCentral

34.

Lovato A, Lionello M, Staffieri A et al (2015) A higher angiogenin expression is associated with a nonnuclear Maspin location in laryngeal carcinoma. Clin Exp Otorhinolaryngol 8:268–274CrossRefPubMedPubMedCentral

Title: Prognostic value of glucosylceramide synthase and P-glycoprotein expression in oral cavity cancer
Authors: Ji Won Kim
Yangsoon Park
Jong-Lyel Roh
Kyung-Ja Cho
Seung-Ho Choi
Soon Yuhl Nam
Sang Yoon Kim
Publication date: 01-10-2016
Publisher: Springer Japan
Published in: International Journal of Clinical Oncology / Issue 5/2016
Print ISSN: 1341-9625
Electronic ISSN: 1437-7772
DOI: https://doi.org/10.1007/s10147-016-0973-1

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 5/2016

Comparison between surgery and definitive chemoradiotherapy for patients with resectable esophageal squamous cell carcinoma: a propensity score analysis

Association of atopic diseases and parvovirus B19 with acute lymphoblastic leukemia in childhood and adolescence in the northeast of Brazil

Putative risk factors for postoperative pneumonia which affects poor prognosis in patients with gastric cancer

Impact of Gleason pattern 5 including tertiary pattern 5 on outcomes of salvage treatment for biochemical recurrence in pT2-3N0M0 prostate cancer

Identification of adverse events that have a negative impact on quality of life in a clinical trial comparing docetaxel versus S-1 with cisplatin in lung cancer

Preoperative biliary drainage-related inflammation is associated with shorter survival in biliary tract cancer patients

Keynote webinar | Spotlight on antibody–drug conjugates in cancer